Hospital
Noxubee General Critical Access Hospital
Noxubee General Critical Access Hospital was paid $3.94M by Medicaid between Jan 2018 and Dec 2024, across 99 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.
33Billing provider infoNOXUBEE GENERAL CRITICAL ACCESS HOSPITAL
MACON, MS 39341
MACON, MS 39341
33aNPI1902844194assigned 06/02/2006
33bProvider typeCritical Access Hospital
28Total paid$3.94M
24GClaims199,970
24DCodes billed99
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Mississippi
Rank by total paid#17 of 32
Median peer was paid$3.94M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 29,053 | $623K | |
| 2019 | 30,082 | $750K | |
| 2020 | 19,435 | $428K | |
| 2021 | 26,786 | $565K | |
| 2022 | 28,445 | $628K | |
| 2023 | 39,669 | $489K | |
| 2024incomplete | 26,500 | $456K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 7,851 | 5,703 | $730K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 9.8% | 13,293 | 1,628 | $388K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 7.0% | 9,611 | 7,604 | $275K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.2% | 1,931 | 1,221 | $243K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 5.9% | 17,562 | 8,071 | $234K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 5.6% | 7,143 | 5,426 | $221K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.1% | 1,763 | 1,155 | $161K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.6% | 920 | 720 | $143K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.6% | 7,784 | 1,211 | $141K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 1,581 | 1,247 | $100K |
| 80053 | Comprehensive metabolic panel | 2.5% | 12,887 | 9,655 | $97K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 15,821 | 11,941 | $92K |
87 more codes
| 71045 | Radiologic examination, chest; single view | 2.1% | 2,423 | $83K |
| G0378 | Hospital observation service, per hour | 1.7% | 342 | $68K |
| 86063 | 1.7% | 12,209 | $67K | |
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 2,122 | $62K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 3,084 | $56K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.3% | 3,120 | $51K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 652 | $49K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 440 | $46K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 19,928 | $45K |
| 83880 | 1.1% | 1,788 | $43K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.0% | 429 | $41K |
| 83735 | <1% | 8,326 | $37K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 390 | $35K |
| 80061 | Lipid panel | <1% | 3,373 | $30K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 273 | $30K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 548 | $29K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 291 | $29K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 113 | $25K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,441 | $22K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,723 | $20K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,009 | $18K |
| 84484 | <1% | 2,039 | $18K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 672 | $17K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 672 | $17K |
| 81001 | <1% | 6,494 | $17K | |
| 82553 | <1% | 1,909 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 782 | $15K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 281 | $11K |
| 82550 | <1% | 2,017 | $11K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 475 | $10K |
| 87807 | <1% | 800 | $9K | |
| 73560 | <1% | 214 | $8K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 487 | $7K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 340 | $6K |
| 97116 | <1% | 543 | $5K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 396 | $5K |
| 80305 | <1% | 662 | $5K | |
| 82607 | <1% | 388 | $4K | |
| 81000 | <1% | 1,986 | $4K | |
| 81025 | <1% | 713 | $4K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 16 | $3K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 28 | $3K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 2,338 | $3K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 12 | $2K |
| 73630 | <1% | 66 | $2K | |
| 82728 | <1% | 166 | $2K | |
| 83550 | <1% | 251 | $2K | |
| 82150 | <1% | 284 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 41 | $2K |
| 83540 | <1% | 251 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 36 | $1K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 14 | $1K |
| 97162 | <1% | 44 | $1K | |
| 87088 | <1% | 291 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 583 | $1K |
| 83655 | <1% | 108 | $1K | |
| 82570 | <1% | 461 | $1K | |
| 85610 | <1% | 304 | $1K | |
| 96367 | <1% | 33 | $978.60 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 446 | $958.95 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 552 | $803.48 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 934 | $774.81 |
| 85018 | <1% | 465 | $739.14 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 576 | $707.22 |
| 93000 | <1% | 133 | $702.23 | |
| 87210 | <1% | 181 | $691.18 | |
| 84156 | <1% | 412 | $674.61 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 653 | $666.40 |
| 85014 | <1% | 396 | $658.20 | |
| 73030 | <1% | 14 | $651.84 | |
| 83690 | <1% | 155 | $605.14 | |
| 81002 | <1% | 293 | $588.42 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 337 | $393.12 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 23 | $208.96 |
| 87077 | <1% | 28 | $160.23 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 32 | $148.80 |
| 82746 | <1% | 13 | $105.84 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 100 | $98.53 |
| 82947 | <1% | 80 | $47.87 | |
| 87184 | <1% | 15 | $40.38 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 416 | $32.80 |
| 84550 | <1% | 21 | $24.42 | |
| 81015 | <1% | 157 | $19.25 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 25 | $8.80 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 31 | $0.00 |
| 94760 | 0% | 36 | $0.00 | |
| 96376 | 0% | 78 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCKAY, DANNY (ADMINISTRATOR)
| Provider | Location | Paid |
|---|---|---|
| Noxubee General Critical Access Hospital | Macon, MS | $2.41M |
| Noxubee General Critical Access Hospital | Macon, MS | $676K |
| Noxubee General Critical Access Hospital | Brooksville, MS | $417K |
| Noxubee General Critical Access Hospital | Macon, MS | $15K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.